{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:00:30Z","timestamp":1793833230658,"version":"4.6.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"am","delay-in-days":406,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1053\/j.seminhematol.2024.11.003","type":"journal-article","created":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T16:11:42Z","timestamp":1731773502000},"page":"50-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunocompetent mouse models of multiple myeloma"],"prefix":"10.1053","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"Peter Leif","family":"Bergsagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Chesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1053\/j.seminhematol.2024.11.003_bib0001","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1172\/JCI61188","article-title":"Molecular pathogenesis of multiple myeloma and its premalignant precursor","volume":"122","author":"Kuehl","year":"2012","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0002","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1038\/s41467-024-48091-w","article-title":"The genomic landscape of Vk*MYC myeloma highlights shared pathways of transformation between mice and humans","volume":"15","author":"Maura","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0003","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.11.003_bib0004","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219439120","article-title":"Mouse models of human multiple myeloma subgroups","volume":"120","author":"Winkler","year":"2023","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"3","key":"10.1053\/j.seminhematol.2024.11.003_bib0005","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nat Med"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.11.003_bib0006","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ccr.2008.01.007","article-title":"AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies","volume":"13","author":"Chesi","year":"2008","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.11.003_bib0007","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.11.003_bib0008","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1084\/jem.20031030","article-title":"Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy","volume":"198","author":"Dhodapkar","year":"2003","journal-title":"J Exp Med"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.11.003_bib0009","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0010","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1038\/s41467-022-33944-z","article-title":"Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis","volume":"13","author":"Boiarsky","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.11.003_bib0011","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","article-title":"Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.11.003_bib0012","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","article-title":"The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape","volume":"22","author":"de Jong","year":"2021","journal-title":"Nat Immunol"},{"issue":"10","key":"10.1053\/j.seminhematol.2024.11.003_bib0013","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.11.003_bib0014","doi-asserted-by":"crossref","first-page":"634-48 e5","DOI":"10.1016\/j.ccell.2018.02.007","article-title":"Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the Multiple myeloma microenvironment","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1053\/j.seminhematol.2024.11.003_bib0015","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1182\/bloodadvances.2021005327","article-title":"Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFalpha","volume":"5","author":"Akhmetzyanova","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.11.003_bib0016","doi-asserted-by":"crossref","first-page":"e9870","DOI":"10.1371\/journal.pone.0009870","article-title":"Tgf-beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth","volume":"5","author":"Takeuchi","year":"2010","journal-title":"PloS one"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.11.003_bib0017","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0018","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1158\/2643-3230.BCD-23-0061","article-title":"ETV4-Dependent transcriptional plasticity maintains MYC expression and results in IMiD resistance in multiple myeloma","volume":"5","author":"Neri","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0019","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2643-3230.BCD-23-0062","article-title":"Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma","volume":"5","author":"Welsh","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.11.003_bib0020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41375-018-0216-8","article-title":"Spectrum and functional validation of PSMB5 mutations in multiple myeloma","volume":"33","author":"Barrio","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.11.003_bib0021","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.11.003_bib0022","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3181\/00379727-101-24970","article-title":"Induction of plasma-cell neoplasms and fibrosarcomas in BALB\/c mice carrying diffusion chambers","volume":"101","author":"Merwin","year":"1959","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1053\/j.seminhematol.2024.11.003_bib0023","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1034\/j.1600-065X.2003.00061.x","article-title":"Neoplastic development in plasma cells","volume":"194","author":"Potter","year":"2003","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood.V74.1.1.1","article-title":"The biology of interleukin-6","volume":"74","author":"Kishimoto","year":"1989","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.11.003_bib0025","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1172\/JCI69094","article-title":"GP130 activation induces myeloma and collaborates with MYC","volume":"124","author":"Dechow","year":"2014","journal-title":"J Clin Invest"},{"issue":"25","key":"10.1053\/j.seminhematol.2024.11.003_bib0026","doi-asserted-by":"crossref","first-page":"14982","DOI":"10.1073\/pnas.2431627100","article-title":"Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene","volume":"100","author":"Bliskovsky","year":"2003","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"10.1053\/j.seminhematol.2024.11.003_bib0027","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1073\/pnas.95.5.2429","article-title":"Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1","volume":"95","author":"Zhang","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"15","key":"10.1053\/j.seminhematol.2024.11.003_bib0028","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1038\/sj.onc.1206257","article-title":"p16 INK4a gene promoter variation and differential binding of a repressor, the ras-responsive zinc-finger transcription factor, RREB","volume":"22","author":"Zhang","year":"2003","journal-title":"Oncogene"},{"issue":"2 Pt 1","key":"10.1053\/j.seminhematol.2024.11.003_bib0029","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/0092-8674(82)90137-4","article-title":"Novel myc oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas","volume":"31","author":"Shen-Ong","year":"1982","journal-title":"Cell"},{"key":"10.1053\/j.seminhematol.2024.11.003_bib0030","first-page":"649","article-title":"Bone lesions produced by transplanted plasma-cell tumors in BALB\/c mice","volume":"28","author":"Kobayashi","year":"1962","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.11.003_bib0031","doi-asserted-by":"crossref","first-page":"e51892","DOI":"10.1371\/journal.pone.0051892","article-title":"A novel mouse model for multiple myeloma (MOPC315.BM) that allows noninvasive spatiotemporal detection of osteolytic disease","volume":"7","author":"Hofgaard","year":"2012","journal-title":"PloS one"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.11.003_bib0032","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood-2009-08-237941","article-title":"IL-6 and MYC collaborate in plasma cell tumor formation in mice","volume":"115","author":"Rutsch","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.11.003_bib0033","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.3324\/haematol.2022.282538","article-title":"IL6Myc mouse is an immunocompetent model for the development of aggressive multiple myeloma","volume":"108","author":"Pisano","year":"2023","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0034","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/0008-5472.BCD-19-0068","article-title":"Monosomic loss of MIR15A\/MIR16-1 is a driver of multiple myeloma proliferation and disease progression","volume":"1","author":"Chesi","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.11.003_bib0035","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.1997.409","article-title":"Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL\/KaLwRij mouse","volume":"76","author":"Vanderkerken","year":"1997","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.11.003_bib0036","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/bjc.1996.277","article-title":"Follow-up of bone lesions in an experimental multiple myeloma mouse model: description of an in vivo technique using radiography dedicated for mammography","volume":"73","author":"Vanderkerken","year":"1996","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.11.003_bib0037","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1182\/blood-2002-10-3000","article-title":"Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis","volume":"101","author":"Asosingh","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.11.003_bib0038","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/sj.thj.6200052","article-title":"The 5TMM series: a useful in vivo mouse model of human multiple myeloma","volume":"1","author":"Asosingh","year":"2000","journal-title":"Hematol J"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0039","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1038\/s41598-018-33396-w","article-title":"The genetic landscape of 5T models for multiple myeloma","volume":"8","author":"Maes","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.11.003_bib0040","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ijc.10642","article-title":"Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells","volume":"101","author":"Van Valckenborgh","year":"2002","journal-title":"Int J Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2024.11.003_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127828","article-title":"Whole genome sequence of multiple myeloma-prone C57BL\/KaLwRij mouse strain suggests the origin of disease involves multiple cell types","volume":"10","author":"Amend","year":"2015","journal-title":"PLoS One"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.11.003_bib0042","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.neo.2014.07.002","article-title":"SAMSN1 is a tumor suppressor gene in multiple myeloma","volume":"16","author":"Noll","year":"2014","journal-title":"Neoplasia"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.11.003_bib0043","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1096\/fba.2020-00027","article-title":"Characterization of the role of Samsn1 loss in multiple myeloma development","volume":"2","author":"Friend","year":"2020","journal-title":"FASEB Bioadv"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0044","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2024.11.003_bib0045","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1038\/leu.2012.113","article-title":"Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow","volume":"26","author":"Van Valckenborgh","year":"2012","journal-title":"Leukemia"},{"issue":"5-6","key":"10.1053\/j.seminhematol.2024.11.003_bib0046","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10585-006-9038-6","article-title":"Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model","volume":"23","author":"Menu","year":"2006","journal-title":"Clin Exp Metastasis"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.11.003_bib0047","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.neo.2017.09.004","article-title":"DNA barcoding reveals habitual clonal dominance of myeloma plasma cells in the bone marrow microenvironment","volume":"19","author":"Hewett","year":"2017","journal-title":"Neoplasia"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0048","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood.2018880930","article-title":"A niche-dependent myeloid transcriptome signature defines dormant myeloma cells","volume":"134","author":"Khoo","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2024.11.003_bib0049","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/leu.2014.70","article-title":"Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma","volume":"28","author":"Affer","year":"2014","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.seminhematol.2024.11.003_bib0050","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.hoc.2023.12.014","article-title":"Immunocompetent mouse models of multiple myeloma: therapeutic implications","volume":"38","author":"Du","year":"2024","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0051","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1038\/s41467-018-07305-8","article-title":"Microbiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression","volume":"9","author":"Calcinotto","year":"2018","journal-title":"Nat Commun"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.11.003_bib0052","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1053\/j.seminhematol.2024.11.003_bib0053","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1182\/blood-2018-01-825265","article-title":"TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma","volume":"132","author":"Guillerey","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.11.003_bib0054","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"17","key":"10.1053\/j.seminhematol.2024.11.003_bib0055","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1182\/bloodadvances.2022008118","article-title":"Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA","volume":"6","author":"Casey","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.11.003_bib0056","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3324\/haematol.2023.283758","article-title":"Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy","volume":"109","author":"Casey","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1053\/j.seminhematol.2024.11.003_bib0057","first-page":"2131","article-title":"Harnessing the cytotoxic granule exocytosis to augment the efficacy of T-cell-engaging bispecific antibody therapy","volume":"109","author":"Casey","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"10.1053\/j.seminhematol.2024.11.003_bib0058","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/nm.4229","article-title":"IAP antagonists induce anti-tumor immunity in multiple myeloma","volume":"22","author":"Chesi","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0059","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41375-019-0519-4","article-title":"Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination","volume":"34","author":"Akhmetzyanova","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0060","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2020007156","article-title":"Expression of NrasQ61R and MYC transgene in germinal center B cells induces a highly malignant multiple myeloma in mice","volume":"137","author":"Wen","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1053\/j.seminhematol.2024.11.003_bib0061","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41388-023-02684-9","article-title":"Molecular characterization stratifies VQ myeloma cells into two clusters with distinct risk signatures and drug responses","volume":"42","author":"Flietner","year":"2023","journal-title":"Oncogene"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.11.003_bib0062","doi-asserted-by":"crossref","first-page":"e67941","DOI":"10.1371\/journal.pone.0067941","article-title":"Germinal center B-cells resist transformation by Kras independently of tumor suppressor Arf","volume":"8","author":"Mullins","year":"2013","journal-title":"PloS one"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.11.003_bib0063","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1073\/pnas.022643999","article-title":"IL-6 transgenic mouse model for extraosseous plasmacytoma","volume":"99","author":"Kovalchuk","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0064","first-page":"1","article-title":"E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells","volume":"8","author":"Strasser","year":"1993","journal-title":"Oncogene"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.11.003_bib0065","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1074-7613(00)80437-9","article-title":"Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene","volume":"4","author":"Fang","year":"1996","journal-title":"Immunity"},{"issue":"9","key":"10.1053\/j.seminhematol.2024.11.003_bib0066","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1158\/0008-5472.CAN-06-3699","article-title":"A transgenic mouse model of plasma cell malignancy shows phenotypic, cytogenetic, and gene expression heterogeneity similar to human multiple myeloma","volume":"67","author":"Boylan","year":"2007","journal-title":"Cancer Res"},{"issue":"3","key":"10.1053\/j.seminhematol.2024.11.003_bib0067","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/j.1460-2075.1990.tb08187.x","article-title":"An E mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene","volume":"9","author":"Rosenbaum","year":"1990","journal-title":"EMBO J"},{"issue":"4","key":"10.1053\/j.seminhematol.2024.11.003_bib0068","first-page":"811","article-title":"A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas","volume":"7","author":"Largaespada","year":"1992","journal-title":"Oncogene"},{"key":"10.1053\/j.seminhematol.2024.11.003_bib0069","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1034\/j.1600-065X.2003.00035.x","article-title":"Multiple myeloma biology: lessons from the 5TMM models","volume":"194","author":"Vanderkerken","year":"2003","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1053\/j.seminhematol.2024.11.003_bib0070","doi-asserted-by":"crossref","first-page":"10616","DOI":"10.1038\/s41598-022-14114-z","article-title":"Ponatinib sensitizes myeloma cells to MEK inhibition in the high-risk VQ model","volume":"12","author":"Flietner","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"10.1053\/j.seminhematol.2024.11.003_bib0071","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S8756-3282(97)00056-2","article-title":"A murine model of human myeloma bone disease","volume":"20","author":"Garrett","year":"1997","journal-title":"Bone"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196324001276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T14:07:57Z","timestamp":1741961277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196324001276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0037196324001276"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.11.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunocompetent mouse models of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2024.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}